[Editorial] A cure for Crohn's disease by 2032

In today's Lancet, Séverine Vermeire and colleagues report the results of FITZROY, a phase 2 randomised controlled trial that compared the JAK1 inhibitor filgotinib with placebo for clinical remission in patients with moderate-to-severe Crohn's disease. Although modestly sized, short-term, and preliminary, the study offers promise for several reasons: the different approach to cytokine blockade, oral dosing, stratification by prior treatment with anti-TNF compounds, and the use of meaningful patient-reported outcomes.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jEyfyA
via IFTTT